Natera Inc's Fiscal Year is From January To December - All Figures are in Percent.
The item "Operating-Return-On-Assets" stands at -12.07 percent as of 06/30/2026, the highest value at least since 09/30/2023, the period currently displayed.
As of the end of Natera Inc's second quarter, the item "Operating Return On Assets" stands at -12.07 Percent. This represents an increase of 2.84 percentage points compared to it's value at the end of it's first quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 5.36 compared to the value the year prior.
The Serie's long term average value is -21.89 percent. It's latest available value, on 06/30/2026, is 9.82 higher, compared to it's long term average value.
The Serie's change from it's minimum value, on 06/30/2023, to it's latest available value, on 06/30/2026, is +29.10 .
The Serie's change from it's maximum value, on 06/30/2026, to it's latest available value, on 06/30/2026, is 0.0 .
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Operating Return On Assets | 905,699,262,464.00 |
![]() | Johnson & Johnson - Operating Return On Assets | 486,508,953,600.00 |
![]() | AbbVie Inc - Operating Return On Assets | 399,570,305,024.00 |
![]() | Roche Holding AG - Operating Return On Assets | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Operating Return On Assets | 280,205,508,085.11 |